Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Climb Bio, Inc.
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
June 5, 2026
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
May 26, 2026
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
May 14, 2026
Climb Bio to Present at Upcoming Investor Conferences
May 12, 2026
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
May 5, 2026
Climb Bio, Inc. Announces $110.0 Million Private Placement
April 28, 2026
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
April 8, 2026
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
April 7, 2026
Climb Bio to Present at Upcoming Investor Conferences
February 5, 2026